RT Journal Article
SR Electronic
T1 Study Protocol: LIAM Mc Trial (Linking In with Advice and supports for Men impacted by Metastatic cancer)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.26.24316178
DO 10.1101/2024.10.26.24316178
A1 Noonan, Brendan
A1 Bredin, Philip
A1 Cahill, Anita M.
A1 Corkery, Stephanie
A1 Johnston, Katie E.
A1 Medved, Katarina
A1 Cusack, Anne Marie
A1 Hegarty, Josephine
A1 Saab, Mohamad M
A1 Cushen, Samantha J.
A1 Connolly, Roisin
A1 Palmer, Brendan
A1 Dahly, Darren
A1 Murphy, Mike
A1 Bambury, Richard M.
A1 Gleeson, Jack P.
YR 2024
UL http://medrxiv.org/content/early/2024/10/27/2024.10.26.24316178.abstract
AB Background The improved survival rate for many cancers in high-income countries demands a coordinated multidisciplinary approach to survivorship care and service provision to ensure optimal patient outcomes and quality of life. This study assesses the feasibility of introducing a Men’s Health Initiative supportive care intervention programme in Ireland.Methods This is a single-arm feasibility study involving a 12-week men’s cancer survivorship programme alongside routine follow-up care in patients with advanced genitourinary malignancies. Men with advanced/metastatic genitourinary cancer (including prostate, kidney, urothelial tract, testicular or penile cancer), are eligible to enrol, with a target of 72 participants over a 2-year period.The intervention programme entails a twice-weekly physiotherapy-led exercise programme, along with dietetics, nursing, and psychosocial components, and regular signposting to additional available services. A Pilot Phase involving analysis of data from the first group of 6 participants to complete the programme is planned, before an Expansion Phase. Assessments will occur at baseline, on completion of the 12-week intervention, and 6 months post-intervention, and will include analyses of exercise/activity levels, body composition, muscle strength, psychological wellbeing, quality of life and resources utilised.The primary endpoints are to determine the feasibility and acceptability of introducing a men’s cancer survivorship intervention programme into routine follow-up care in patients with advanced genitourinary malignancies. Secondary endpoints include impact of the intervention programme on quality of life, cancer-related fatigue, maintenance of weight, changes in body composition and changes in dietary intake and diet quality over the study period, as well as self-care agency and its relationship to quality of life and symptoms experienced. A process evaluation will capture the experiences of participation in the study, and the healthcare costs will be examined as part of the economic analysis.Ethical approval was granted in November 2022, with recruitment commencing in May 2023.Discussion The programme described in this protocol provides a supportive and safe environment for the introduction of self-care interventions using a small group-based format supported by individualised counselling according to the participant’s identified needs. Findings will provide direction for the implementation of future supportive care programmes for men’s cancer survivorship care.ClinicalTrials.gov Identifier: NCT05946993; Cancer Trials Ireland #: CTRIAL-IE 23-18; Irish Cancer Society (ICS) Study reference: MHI22BAM, UCC Sponsor Study Code: 22052.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is registered with ClinicalTrials.gov with a trial registration number of NCT05946993, Cancer Trials Ireland CTRIAL-IE 23-18 and UCC #22052.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study will be conducted in accordance with the Declaration of Helsinki, the applicable sections of ICH E6 Good Clinical Practices (15) and the terms of approval of the responsible Clinical Research Ethics Committee of the University’s Teaching Hospital. Full ethical approval for the trial was granted by the Clinical Research Ethics Committee in November 2022 (ECM 4 (v) 01/11/2022). All subsequent amendments to the protocol which impacted or may impact the study's conduct have been or will be submitted as amendments for approval to the ethics committee. The study is registered with ClinicalTrials.gov with a trial registration number of NCT05946993, Cancer Trials Ireland CTRIAL-IE 23-18 and UCC #22052.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.